Agios Pharmaceuticals AGIO Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's operating income?
- Agios Pharmaceuticals (AGIO) reported operating income of -$110.03M in Q1 2026.
- How has Agios Pharmaceuticals's operating income changed year-over-year?
- Agios Pharmaceuticals's operating income decreased by 3.2% year-over-year, from -$106.63M to -$110.03M.
- What is the long-term trend for Agios Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's operating income has grown at a 5.7% compound annual growth rate (CAGR), from -$378.42M to -$472.13M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.